Irhythm Tech (IRTC) Given Coverage Optimism Rating of 0.25

News articles about Irhythm Tech (NASDAQ:IRTC) have been trending positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Irhythm Tech earned a coverage optimism score of 0.25 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.409619116354 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several brokerages have issued reports on IRTC. Zacks Investment Research lowered shares of Irhythm Tech from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. Canaccord Genuity lifted their price target on shares of Irhythm Tech from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, September 22nd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Irhythm Tech currently has an average rating of “Buy” and a consensus price target of $44.40.

Shares of Irhythm Tech (IRTC) traded up 1.48% during midday trading on Tuesday, reaching $51.50. 128,262 shares of the company’s stock traded hands. The company has a 50 day moving average of $50.38 and a 200 day moving average of $50.38. The firm’s market cap is $1.17 billion. Irhythm Tech has a 52-week low of $22.16 and a 52-week high of $53.10.

Irhythm Tech (NASDAQ:IRTC) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Irhythm Tech had a negative net margin of 27.34% and a negative return on equity of 57.23%. The business had revenue of $23.85 million during the quarter, compared to the consensus estimate of $22.10 million. The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. On average, equities analysts predict that Irhythm Tech will post ($1.13) EPS for the current fiscal year.

In related news, Director Vijay K. Lathi sold 34,613 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $49.51, for a total transaction of $1,713,689.63. Following the completion of the sale, the director now owns 1,405 shares in the company, valued at $69,561.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Raymond W. Scott sold 52,903 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $43.59, for a total transaction of $2,306,041.77. The disclosure for this sale can be found here. Insiders have sold 118,014 shares of company stock valued at $5,453,106 in the last 90 days. 23.30% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Irhythm Tech (IRTC) Given Coverage Optimism Rating of 0.25” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://ledgergazette.com/2017/10/17/irhythm-tech-irtc-given-coverage-optimism-rating-of-0-25.html.

Irhythm Tech Company Profile

iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commerci

Several brokerages have issued reports on IRTC. Zacks Investment Research lowered shares of Irhythm Tech from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. Canaccord Genuity lifted their price target on shares of Irhythm Tech from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, September 22nd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Irhythm Tech currently has an average rating of “Buy” and a consensus price target of $44.40.

Shares of Irhythm Tech (IRTC) traded up 1.48% during midday trading on Tuesday, reaching $51.50. 128,262 shares of the company’s stock traded hands. The company has a 50 day moving average of $50.38 and a 200 day moving average of $50.38. The firm’s market cap is $1.17 billion. Irhythm Tech has a 52-week low of $22.16 and a 52-week high of $53.10.

Irhythm Tech (NASDAQ:IRTC) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Irhythm Tech had a negative net margin of 27.34% and a negative return on equity of 57.23%. The business had revenue of $23.85 million during the quarter, compared to the consensus estimate of $22.10 million. The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. On average, equities analysts predict that Irhythm Tech will post ($1.13) EPS for the current fiscal year.

In related news, Director Vijay K. Lathi sold 34,613 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $49.51, for a total transaction of $1,713,689.63. Following the completion of the sale, the director now owns 1,405 shares in the company, valued at $69,561.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Raymond W. Scott sold 52,903 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $43.59, for a total transaction of $2,306,041.77. The disclosure for this sale can be found here. Insiders have sold 118,014 shares of company stock valued at $5,453,106 in the last 90 days. 23.30% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Irhythm Tech (IRTC) Given Coverage Optimism Rating of 0.25” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://ledgergazette.com/2017/10/17/irhythm-tech-irtc-given-coverage-optimism-rating-of-0-25.html.

Irhythm Tech Company Profile

iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.

Insider Buying and Selling by Quarter for Irhythm Tech (NASDAQ:IRTC)

Receive News & Ratings for Irhythm Tech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Tech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply